Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. https://doi.org/10.3322/caac.21492.
Zuniga KB, Chan JM, Ryan CJ, Kenfield SA. Diet and lifestyle considerations for patients with prostate cancer. Urol Oncol. 2020;38(3):105–17. https://doi.org/10.1016/j.urolonc.2019.06.018This is a recent review of randomized controlled trials to provide recommendations on diet and lifestyle considerations for patients diagnosed with prostate cancer.
Wang Y, Jacobs EJ, Shah RA, Stevens VL, Gansler T, McCullough ML. Red and processed meat, poultry, fish, and egg intakes and cause-specific and all-cause mortality among men with nonmetastatic prostate cancer in a U.S. Cohort. Cancer Epidemiol Biomarkers Prev. 2020;29(5):1029–38. https://doi.org/10.1158/1055-9965.EPI-19-1426.
Wilson KM, Mucci LA, Drake BF, Preston MA, Stampfer MJ, Giovannucci E, et al. Meat, fish, poultry, and egg intake at diagnosis and risk of prostate cancer progression. Cancer Prev Res (Phila). 2016;9(12):933–41. https://doi.org/10.1158/1940-6207.CAPR-16-0070.
Yang M, Kenfield SA, Van Blarigan EL, Batista JL, Sesso HD, Ma J, et al. Dietary patterns after prostate cancer diagnosis in relation to disease-specific and total mortality. Cancer Prev Res (Phila). 2015;8(6):545–51. https://doi.org/10.1158/1940-6207.CAPR-14-0442.
Richman EL, Stampfer MJ, Paciorek A, Broering JM, Carroll PR, Chan JM. Intakes of meat, fish, poultry, and eggs and risk of prostate cancer progression. Am J Clin Nutr. 2010;91(3):712–21. https://doi.org/10.3945/ajcn.2009.28474.
Chan JM, Holick CN, Leitzmann MF, Rimm EB, Willett WC, Stampfer MJ, et al. Diet after diagnosis and the risk of prostate cancer progression, recurrence, and death (United States). Cancer Causes Control. 2006;17(2):199–208. https://doi.org/10.1007/s10552-005-0413-4.
Richman EL, Kenfield SA, Stampfer MJ, Giovannucci EL, Chan JM. Egg, red meat, and poultry intake and risk of lethal prostate cancer in the prostate-specific antigen-era: incidence and survival. Cancer Prev Res (Phila). 2011;4(12):2110–21. https://doi.org/10.1158/1940-6207.CAPR-11-0354.
Tat D, Kenfield SA, Cowan JE, Broering JM, Carroll PR, Van Blarigan EL, et al. Milk and other dairy foods in relation to prostate cancer recurrence: data from the cancer of the prostate strategic urologic research endeavor (CaPSURE). Prostate. 2018;78(1):32–9. https://doi.org/10.1002/pros.23441.
Downer MK, Batista JL, Mucci LA, Stampfer MJ, Epstein MM, Hakansson N, et al. Dairy intake in relation to prostate cancer survival. Int J Cancer. 2017;140(9):2060–9. https://doi.org/10.1002/ijc.30642.
Pettersson A, Kasperzyk JL, Kenfield SA, Richman EL, Chan JM, Willett WC, et al. Milk and dairy consumption among men with prostate cancer and risk of metastases and prostate cancer death. Cancer Epidemiol Biomarkers Prev. 2012;21(3):428–36. https://doi.org/10.1158/1055-9965.EPI-11-1004.
Van Blarigan EL, Kenfield SA, Yang M, Sesso HD, Ma J, Stampfer MJ, et al. Fat intake after prostate cancer diagnosis and mortality in the Physicians’ Health Study. Cancer Causes Control. 2015;26(8):1117–26. https://doi.org/10.1007/s10552-015-0606-4.
Richman EL, Kenfield SA, Chavarro JE, Stampfer MJ, Giovannucci EL, Willett WC, et al. Fat intake after diagnosis and risk of lethal prostate cancer and all-cause mortality. JAMA Intern Med. 2013;173(14):1318–26. https://doi.org/10.1001/jamainternmed.2013.6536.
Epstein MM, Kasperzyk JL, Mucci LA, Giovannucci E, Price A, Wolk A, et al. Dietary fatty acid intake and prostate cancer survival in Orebro County. Sweden. Am J Epidemiol. 2012;176(3):240–52. https://doi.org/10.1093/aje/kwr520.
Strom SS, Yamamura Y, Forman MR, Pettaway CA, Barrera SL, DiGiovanni J. Saturated fat intake predicts biochemical failure after prostatectomy. Int J Cancer. 2008;122(11):2581–5. https://doi.org/10.1002/ijc.23414.
Meyer F, Bairati I, Shadmani R, Fradet Y, Moore L. Dietary fat and prostate cancer survival. Cancer Causes Control. 1999;10(4):245–51. https://doi.org/10.1023/a:1008913307947.
Richman EL, Carroll PR, Chan JM. Vegetable and fruit intake after diagnosis and risk of prostate cancer progression. Int J Cancer. 2012;131(1):201–10. https://doi.org/10.1002/ijc.26348.
Downer MK, Kenfield SA, Stampfer MJ, Wilson KM, Dickerman BA, Giovannucci EL, et al. Alcohol intake and risk of lethal prostate cancer in the health professionals follow-up study. J Clin Oncol. 2019;37(17):1499–511. https://doi.org/10.1200/JCO.18.02462.
Farris MS, Courneya KS, Kopciuk KA, McGregor SE, Friedenreich CM. Post-diagnosis alcohol intake and prostate cancer survival: a population-based cohort study. Int J Cancer. 2018;143(2):253–62. https://doi.org/10.1002/ijc.31307.
Nair-Shalliker V, Bang A, Egger S, Clements M, Gardiner RA, Kricker A, et al. Post-treatment levels of plasma 25- and 1,25-dihydroxy vitamin D and mortality in men with aggressive prostate cancer. Sci Rep. 2020;10(1):7736. https://doi.org/10.1038/s41598-020-62182-w.
Kenfield SA, Van Blarigan EL, Du Pre N, Stampfer MJ, LG E, Chan JM. Selenium supplementation and prostate cancer mortality. J Natl Cancer Inst. 2015;107(1):360. https://doi.org/10.1093/jnci/dju360.
Holt SK, Kolb S, Fu R, Horst R, Feng Z, Stanford JL. Circulating levels of 25-hydroxyvitamin D and prostate cancer prognosis. Cancer Epidemiol. 2013;37(5):666–70. https://doi.org/10.1016/j.canep.2013.07.005.
Jackson MD, Tulloch-Reid MK, McCaw-Binns AM, Aiken W, Ferguson TS, Bennett NR, et al. Central adiposity at diagnosis may reduce prostate cancer-specific mortality in African-Caribbean men with prostate cancer: 10-year follow-up of participants in a case-control study. Cancer Causes Control. 2020;31(7):651–62. https://doi.org/10.1007/s10552-020-01306-z.
Troeschel AN, Hartman TJ, Jacobs EJ, Stevens VL, Gansler T, Flanders WD, et al. Postdiagnosis body mass index, weight change, and mortality from prostate cancer, cardiovascular disease, and all causes among survivors of nonmetastatic prostate cancer. J Clin Oncol. 2020;38(18):2018–27. https://doi.org/10.1200/JCO.19.02185.
Leal-Garcia M, Canto P, Cardenas-Cardenas E, Feria-Bernal G, Garcia-Garcia E, Mendez JP. Overweight and obesity in men with prostate cancer do not constitute risk factors for biochemical recurrence. Aging Male. 2020:1–6. https://doi.org/10.1080/13685538.2020.1764523.
Vidal AC, Oyekunle T, Howard LE, De Hoedt AM, Kane CJ, Terris MK, et al. Obesity, race, and long-term prostate cancer outcomes. Cancer. 2020;126:3733–41. https://doi.org/10.1002/cncr.32906.
Langlais CS, Cowan JE, Neuhaus J, Kenfield SA, Van Blarigan EL, Broering JM, et al. Obesity at Diagnosis and prostate cancer prognosis and recurrence risk following primary treatment by radical prostatectomy. Cancer Epidemiol Biomarkers Prev. 2019;28(11):1917–25. https://doi.org/10.1158/1055-9965.EPI-19-0488.
Freedland SJ, Branche BL, Howard LE, Hamilton RJ, Aronson WJ, Terris MK, et al. Obesity, risk of biochemical recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. BJU Int. 2019;124(1):69–75. https://doi.org/10.1111/bju.14594.
Farris MS, Courneya KS, Kopciuk KA, McGregor SE, Friedenreich CM. Anthropometric measurements and survival after a prostate cancer diagnosis. Br J Cancer. 2018;118(4):607–10. https://doi.org/10.1038/bjc.2017.440.
Vidal AC, Howard LE, Sun SX, Cooperberg MR, Kane CJ, Aronson WJ, et al. Obesity and prostate cancer-specific mortality after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Prostate Cancer Prostatic Dis. 2017;20(1):72–8. https://doi.org/10.1038/pcan.2016.47.
Dickerman BA, Ahearn TU, Giovannucci E, Stampfer MJ, Nguyen PL, Mucci LA, et al. Weight change, obesity and risk of prostate cancer progression among men with clinically localized prostate cancer. Int J Cancer. 2017;141(5):933–44. https://doi.org/10.1002/ijc.30803.
Schiffmann J, Salomon G, Tilki D, Budaus L, Karakiewicz PI, Leyh-Bannurah SR, et al. Radical prostatectomy neutralizes obesity-driven risk of prostate cancer progression. Urol Oncol. 2017;35(5):243–9. https://doi.org/10.1016/j.urolonc.2016.12.014.
Khan S, Cai J, Nielsen ME, Troester MA, Mohler JL, Fontham ETH, et al. The association of diabetes and obesity with prostate cancer progression: HCaP-NC. Prostate. 2017;77(8):878–87. https://doi.org/10.1002/pros.23342.
Wang LS, Murphy CT, Ruth K, Zaorsky NG, Smaldone MC, Sobczak ML, et al. Impact of obesity on outcomes after definitive dose-escalated intensity-modulated radiotherapy for localized prostate cancer. Cancer. 2015;121(17):3010–7. https://doi.org/10.1002/cncr.29472.
Bonn SE, Holmberg E, Hugosson J, Balter K. Is leisure time sitting associated with mortality rates among men diagnosed with localized prostate cancer? Eur J Cancer Prev. 2019;29:134–40. https://doi.org/10.1097/CEJ.0000000000000523.
Dai JY, Wang B, Wang X, Cheng A, Kolb S, Stanford JL, et al. Vigorous physical activity is associated with lower risk of metastatic-lethal progression in prostate cancer and hypomethylation in the CRACR2A gene. Cancer Epidemiol Biomarkers Prev. 2019;28(2):258–64. https://doi.org/10.1158/1055-9965.EPI-18-0622.
Guy DE, Vandersluis A, Klotz LH, Fleshner N, Kiss A, Parker C, et al. Total energy expenditure and vigorous-intensity physical activity are associated with reduced odds of reclassification among men on active surveillance. Prostate Cancer Prostatic Dis. 2018;21(2):187–95. https://doi.org/10.1038/s41391-017-0010-0.
Wang Y, Jacobs EJ, Gapstur SM, Maliniak ML, Gansler T, McCullough ML, et al. Recreational physical activity in relation to prostate cancer-specific mortality among men with nonmetastatic prostate cancer. Eur Urol. 2017;72(6):931–9. https://doi.org/10.1016/j.eururo.2017.06.037.
Friedenreich CM, Wang Q, Neilson HK, Kopciuk KA, McGregor SE, Courneya KS. Physical activity and survival after prostate cancer. Eur Urol. 2016;70(4):576–85. https://doi.org/10.1016/j.eururo.2015.12.032.
Vandersluis AD, Guy DE, Klotz LH, Fleshner NE, Kiss A, Parker C, et al. The role of lifestyle characteristics on prostate cancer progression in two active surveillance cohorts. Prostate Cancer Prostatic Dis. 2016;19(3):305–10. https://doi.org/10.1038/pcan.2016.22.
Bonn SE, Sjolander A, Lagerros YT, Wiklund F, Stattin P, Holmberg E, et al. Physical activity and survival among men diagnosed with prostate cancer. Cancer Epidemiol Biomarkers Prev. 2015;24(1):57–64. https://doi.org/10.1158/1055-9965.EPI-14-0707.
Richman EL, Kenfield SA, Stampfer MJ, Paciorek A, Carroll PR, Chan JM. Physical activity after diagnosis and risk of prostate cancer progression: data from the cancer of the prostate strategic urologic research endeavor. Cancer Res. 2011;71(11):3889–95. https://doi.org/10.1158/0008-5472.CAN-10-3932.
Kenfield SA, Stampfer MJ, Giovannucci E, Chan JM. Physical activity and survival after prostate cancer diagnosis in the health professionals follow-up study. J Clin Oncol. 2011;29(6):726–32. https://doi.org/10.1200/JCO.2010.31.5226.
Riviere P, Kumar A, Luterstein E, Vitzthum LK, Nalawade V, Sarkar RR, et al. Tobacco smoking and death from prostate cancer in US veterans. Prostate Cancer Prostatic Dis. 2020;23(2):252–9. https://doi.org/10.1038/s41391-019-0178-6.
Sato N, Shiota M, Shiga KI, Takeuchi A, Inokuchi J, Tatsugami K, et al. Smoking effect on oncological outcome among men with prostate cancer after radical prostatectomy. Jpn J Clin Oncol. 2017;47(5):453–7. https://doi.org/10.1093/jjco/hyx013.
Steinberger E, Kollmeier M, McBride S, Novak C, Pei X, Zelefsky MJ. Cigarette smoking during external beam radiation therapy for prostate cancer is associated with an increased risk of prostate cancer-specific mortality and treatment-related toxicity. BJU Int. 2015;116(4):596–603. https://doi.org/10.1111/bju.12969.
Rieken M, Shariat SF, Kluth LA, Fajkovic H, Rink M, Karakiewicz PI, et al. Association of cigarette smoking and smoking cessation with biochemical recurrence of prostate cancer in patients treated with radical prostatectomy. Eur Urol. 2015;68(6):949–56. https://doi.org/10.1016/j.eururo.2015.05.038.
Moreira DM, Aronson WJ, Terris MK, Kane CJ, Amling CL, Cooperberg MR, et al. Cigarette smoking is associated with an increased risk of biochemical disease recurrence, metastasis, castration-resistant prostate cancer, and mortality after radical prostatectomy: results from the SEARCH database. Cancer. 2014;120(2):197–204. https://doi.org/10.1002/cncr.28423.
Ngo TC, Lee JJ, Brooks JD, Nolley R, Ferrari M, Presti JC Jr. Smoking and adverse outcomes at radical prostatectomy. Urol Oncol. 2013;31(6):749–54. https://doi.org/10.1016/j.urolonc.2011.06.013.
Oh JJ, Hong SK, Jeong CW, Byun SS, Lee SE. Significance of smoking status regarding outcomes after radical prostatectomy. Int Urol Nephrol. 2012;44(1):119–24. https://doi.org/10.1007/s11255-011-9964-3.
Joshu CE, Mondul AM, Meinhold CL, Humphreys EB, Han M, Walsh PC, et al. Cigarette smoking and prostate cancer recurrence after prostatectomy. J Natl Cancer Inst. 2011;103(10):835–8. https://doi.org/10.1093/jnci/djr124.
Gong Z, Agalliu I, Lin DW, Stanford JL, Kristal AR. Cigarette smoking and prostate cancer-specific mortality following diagnosis in middle-aged men. Cancer Causes Control. 2008;19(1):25–31. https://doi.org/10.1007/s10552-007-9066-9.
Pantarotto J, Malone S, Dahrouge S, Gallant V, Eapen L. Smoking is associated with worse outcomes in patients with prostate cancer treated by radical radiotherapy. BJU Int. 2007;99(3):564–9. https://doi.org/10.1111/j.1464-410X.2006.06656.x.
Merrick GS, Butler WM, Wallner KE, Galbreath RW, Lief JH, Adamovich E. Effect of cigarette smoking on biochemical outcome after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys. 2004;58(4):1056–62. https://doi.org/10.1016/j.ijrobp.2003.08.021.
Pickles T, Liu M, Berthelet E, Kim-Sing C, Kwan W, Tyldesley S, et al. The effect of smoking on outcome following external radiation for localized prostate cancer. J Urol. 2004;171(4):1543–6. https://doi.org/10.1097/01.ju.0000118292.25214.a4.
Oefelein MG, Resnick MI. Association of tobacco use with hormone refractory disease and survival of patients with prostate cancer. J Urol. 2004;171(6 Pt 1):2281–4. https://doi.org/10.1097/01.ju.0000125123.46733.93.
Keto CJ, Aronson WJ, Terris MK, Presti JC, Kane CJ, Amling CL, et al. Obesity is associated with castration-resistant disease and metastasis in men treated with androgen deprivation therapy after radical prostatectomy: results from the SEARCH database. BJU Int. 2012;110(4):492–8. https://doi.org/10.1111/j.1464-410X.2011.10754.x.
Negron R, Vasquez A, Nieves M, Guerrios L, Irizarry-Ramirez M. Body mass index affects the diagnosis and progression of prostate cancer in Hispanics. Ethn Dis. 2010;20(1 Suppl 1):S1-168-72.
Efstathiou JA, Bae K, Shipley WU, Hanks GE, Pilepich MV, Sandler HM, et al. Obesity and mortality in men with locally advanced prostate cancer: analysis of RTOG 85-31. Cancer. 2007;110(12):2691–9. https://doi.org/10.1002/cncr.23093.
Bonn SE, Wiklund F, Sjolander A, Szulkin R, Stattin P, Holmberg E, et al. Body mass index and weight change in men with prostate cancer: progression and mortality. Cancer Causes Control. 2014;25(8):933–43. https://doi.org/10.1007/s10552-014-0393-3.
Bhindi B, Kulkarni GS, Finelli A, Alibhai SM, Hamilton RJ, Toi A, et al. Obesity is associated with risk of progression for low-risk prostate cancers managed expectantly. Eur Urol. 2014;66(5):841–8. https://doi.org/10.1016/j.eururo.2014.06.005.
Narita S, Mitsuzuka K, Yoneyama T, Tsuchiya N, Koie T, Kakoi N, et al. Impact of body mass index on clinicopathological outcome and biochemical recurrence after radical prostatectomy. Prostate Cancer Prostatic Dis. 2013;16(3):271–6. https://doi.org/10.1038/pcan.2013.16.
Ho T, Gerber L, Aronson WJ, Terris MK, Presti JC, Kane CJ, et al. Obesity, prostate-specific antigen nadir, and biochemical recurrence after radical prostatectomy: biology or technique? Results from the SEARCH database. Eur Urol. 2012;62(5):910–6. https://doi.org/10.1016/j.eururo.2012.08.015.
Kane CJ, Im R, Amling CL, Presti JC Jr, Aronson WJ, Terris MK, et al. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology. 2010;76(3):695–700. https://doi.org/10.1016/j.urology.2009.12.073.
van Roermund JG, Hinnen KA, Battermann JJ, Witjes JA, Bosch JL, Kiemeney LA, et al. Body mass index is not a prognostic marker for prostate-specific antigen failure and survival in Dutch men treated with brachytherapy. BJU Int. 2010;105(1):42–8. https://doi.org/10.1111/j.1464-410X.2009.08687.x.
King CR, Spiotto MT, Kapp DS. Obesity and risk of biochemical failure for patients receiving salvage radiotherapy after prostatectomy. Int J Radiat Oncol Biol Phys. 2009;73(4):1017–22. https://doi.org/10.1016/j.ijrobp.2008.05.041.
Jayachandran J, Banez LL, Aronson WJ, Terris MK, Presti JC Jr, Amling CL, et al. Obesity as a predictor of adverse outcome across black and white race: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer. 2009;115(22):5263–71. https://doi.org/10.1002/cncr.24571.
Davies BJ, Smaldone MC, Sadetsky N, Dall’era M, Carroll PR. The impact of obesity on overall and cancer specific survival in men with prostate cancer. J Urol. 2009;182(1):112–7; discussion 7. https://doi.org/10.1016/j.juro.2009.02.118.
van Roermund JG, Kok DE, Wildhagen MF, Kiemeney LA, Struik F, Sloot S, et al. Body mass index as a prognostic marker for biochemical recurrence in Dutch men treated with radical prostatectomy. BJU Int. 2009;104(3):321–5. https://doi.org/10.1111/j.1464-410X.2009.08404.x.
Efstathiou JA, Skowronski RY, Coen JJ, Grocela JA, Hirsch AE, Zietman AL. Body mass index and prostate-specific antigen failure following brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys. 2008;71(5):1302–8. https://doi.org/10.1016/j.ijrobp.2007.11.073.
Magheli A, Rais-Bahrami S, Trock BJ, Humphreys EB, Partin AW, Han M, et al. Impact of body mass index on biochemical recurrence rates after radical prostatectomy: an analysis utilizing propensity score matching. Urology. 2008;72(6):1246–51. https://doi.org/10.1016/j.urology.2008.01.052.
Hisasue S, Yanase M, Shindo T, Iwaki H, Fukuta F, Nishida S, et al. Influence of body mass index and total testosterone level on biochemical recurrence following radical prostatectomy. Jpn J Clin Oncol. 2008;38(2):129–33. https://doi.org/10.1093/jjco/hym162.
Freedland SJ, Sun L, Kane CJ, Presti JC Jr, Terris MK, Amling CL, et al. Obesity and oncological outcome after radical prostatectomy: impact of prostate-specific antigen-based prostate cancer screening: results from the Shared Equal Access Regional Cancer Hospital and Duke Prostate Center databases. BJU Int. 2008;102(8):969–74. https://doi.org/10.1111/j.1464-410X.2008.07934.x.
Stroup SP, Cullen J, Auge BK, L’Esperance JO, Kang SK. Effect of obesity on prostate-specific antigen recurrence after radiation therapy for localized prostate cancer as measured by the 2006 Radiation Therapy Oncology Group-American Society for Therapeutic Radiation and Oncology (RTOG-ASTRO) Phoenix consensus definition. Cancer. 2007;110(5):1003–9. https://doi.org/10.1002/cncr.22873.
Spangler E, Zeigler-Johnson CM, Coomes M, Malkowicz SB, Wein A, Rebbeck TR. Association of obesity with tumor characteristics and treatment failure of prostate cancer in African-American and European American men. J Urol. 2007;178(5):1939–44; discussion 45. https://doi.org/10.1016/j.juro.2007.07.021.
Efstathiou JA, Chen MH, Renshaw AA, Loffredo MJ, D’Amico AV. Influence of body mass index on prostate-specific antigen failure after androgen suppression and radiation therapy for localized prostate cancer. Cancer. 2007;109(8):1493–8. https://doi.org/10.1002/cncr.22564.
Montgomery RB, Goldman B, Tangen CM, Hussain M, Petrylak DP, Page S, et al. Association of body mass index with response and survival in men with metastatic prostate cancer: Southwest Oncology Group trials 8894 and 9916. J Urol. 2007;178(5):1946–51; discussion 51. https://doi.org/10.1016/j.juro.2007.07.026.
Strom SS, Kamat AM, Gruschkus SK, Gu Y, Wen S, Cheung MR, et al. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer. 2006;107(3):631–9. https://doi.org/10.1002/cncr.22025.
Siddiqui SA, Inman BA, Sengupta S, Slezak JM, Bergstralh EJ, Leibovich BC, et al. Obesity and survival after radical prostatectomy: a 10-year prospective cohort study. Cancer. 2006;107(3):521–9. https://doi.org/10.1002/cncr.22030.
Bassett WW, Cooperberg MR, Sadetsky N, Silva S, DuChane J, Pasta DJ, et al. Impact of obesity on prostate cancer recurrence after radical prostatectomy: data from CaPSURE. Urology. 2005;66(5):1060–5. https://doi.org/10.1016/j.urology.2005.05.040.
Strom SS, Wang X, Pettaway CA, Logothetis CJ, Yamamura Y, Do KA, et al. Obesity, weight gain, and risk of biochemical failure among prostate cancer patients following prostatectomy. Clin Cancer Res. 2005;11(19 Pt 1):6889–94. https://doi.org/10.1158/1078-0432.CCR-04-1977.
Freedland SJ, Grubb KA, Yiu SK, Humphreys EB, Nielsen ME, Mangold LA, et al. Obesity and risk of biochemical progression following radical prostatectomy at a tertiary care referral center. J Urol. 2005;174(3):919–22. https://doi.org/10.1097/01.ju.0000169459.78982.d7.
Freedland SJ, Isaacs WB, Mangold LA, Yiu SK, Grubb KA, Partin AW, Epstein JI, Walsh PC, Platz EA Stronger association between obesity and biochemical progression after radical prostatectomy among men treated in the last 10 years. Clin Cancer Res. 2005;11(8):2883-8. doi: https://doi.org/10.1158/1078-0432.CCR-04-2257, 2888.
Freedland SJ, Aronson WJ, Kane CJ, Presti JC Jr, Amling CL, Elashoff D, et al. Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol. 2004;22(3):446–53. https://doi.org/10.1200/JCO.2004.04.181.
Amling CL, Riffenburgh RH, Sun L, Moul JW, Lance RS, Kusuda L, et al. Pathologic variables and recurrence rates as related to obesity and race in men with prostate cancer undergoing radical prostatectomy. J Clin Oncol. 2004;22(3):439–45. https://doi.org/10.1200/JCO.2004.03.132.
American Heart Association. The American Heart Association Diet and Lifestyle Recommendations. American Heart Association.: https://www.heart.org/en/healthy-living/healthy-eating/eat-smart/nutrition-basics/aha-diet-and-lifestyle-recommendations (2020). Accessed September 1, 2020.
American Diabetes Association. What can i eat? American Diabetes Association.: https://www.diabetes.org/blog/what-can-i-eat (2019). Accessed September 1, 2020.
Parsons JK, Zahrieh D, Mohler JL, Paskett E, Hansel DE, Kibel AS, et al. Effect of a behavioral intervention to increase vegetable consumption on cancer progression among men with early-stage prostate cancer: the MEAL randomized clinical trial. JAMA. 2020;323(2):140–8. https://doi.org/10.1001/jama.2019.20207.
National Institute on Alcohol Abuse and Alcoholism. Alcohol’s effects on the body. https://www.niaaa.nih.gov/alcohols-effects-health/alcohols-effects-body Accessed Aug 2020.
American Institute for Cancer Research. Cancer Prevention Recommendations. https://www.aicr.org/reduce-your-cancer-risk/recommendations-for-cancer-prevention/ (2019). Accessed July 2020.
World Cancer Research Fund. Cancer Prevention Recommendations. https://www.wcrf.org/dietandcancer/cancer-prevention-recommendations Accessed July 2020. These are the latest recommendations for cancer prevention from the World Cancer Research Fund, an international organization and authority on cancer prevention research, dedicated to providing practical tools and information to people to help them prevent and survive cancer.
Cao Y, Ma J. Body mass index, prostate cancer-specific mortality, and biochemical recurrence: a systematic review and meta-analysis. Cancer Prev Res (Phila). 2011;4(4):486–501. https://doi.org/10.1158/1940-6207.CAPR-10-0229.
U.S. Department of Health and Human Services. Physical activity guidelines for Americans, 2nd edition. Washington, DC: U.S. Department of Health and Human Services; 2018. These are the latest guidelines from the US Department of Health and Human Services for physical activity, which includes recommendations for prostate cancer survivors.
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. https://doi.org/10.3322/caac.21551.
Miller KD, Goding Sauer A, Ortiz AP, Fedewa SA, Pinheiro PS, Tortolero-Luna G, et al. Cancer statistics for Hispanics/Latinos, 2018. CA Cancer J Clin. 2018;68(6):425–45. https://doi.org/10.3322/caac.21494.
Chinea FM, Patel VN, Kwon D, Lamichhane N, Lopez C, Punnen S, et al. Ethnic heterogeneity and prostate cancer mortality in Hispanic/Latino men: a population-based study. Oncotarget. 2017;8(41):69709–21. https://doi.org/10.18632/oncotarget.19068.